Sugi Predict

Sugi Predict / Compounds / SCHEMBL266080

SCHEMBL266080

SCHEMBL266080

Nc1ccc2c(c1)CCCO2

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PRKCI P41743 1/20 0.49
▸ MAPT P10636 5/20 0.48
▸ GAA P10253 3/20 0.48
▸ KDM4E B2RXH2 2/20 0.48
▸ DYRK1A Q13627 3/20 0.46
▸ CLK1 P49759 1/20 0.46
▸ DYRK1B Q9Y463 1/20 0.46
▸ CTNNB1 P35222 7/20 0.45
▸ WNT3A P56704 7/20 0.45
▸ NOTUM Q6P988 1/20 0.44
▸ SMN1; SMN2 Q16637 3/20 0.43
▸ RAB9A P51151 2/20 0.43
▸ LMNA P02545 2/20 0.43
▸ NPC1 O15118 1/20 0.43
▸ RIPK1 Q13546 1/20 0.40
▸ MEN1 O00255 1/20 0.38
▸ MITF O75030 1/20 0.38
▸ MAPK1 P28482 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ TDP1 Q9NUW8 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29739511 1.00 PRKCI (0.49) PRKCIMAPTGAAKDM4EDYRK1A
SCHEMBL22239364 0.94 PRKCI (0.47) PRKCIMAPTGAAKDM4EDYRK1A
SCHEMBL20330515 0.92 PRKCI (0.46) PRKCIMAPTGAAKDM4EDYRK1A
SCHEMBL20330514 0.92 PRKCI (0.46) PRKCIMAPTGAAKDM4EDYRK1A
SCHEMBL29364809 0.88 PRKCI (0.56) PRKCIMAPTGAAKDM4EDYRK1A
SCHEMBL379230 0.88 PRKCI (0.56) PRKCIMAPTGAAKDM4EDYRK1A
SCHEMBL29739347 0.84 MAPT (0.48) PRKCIMAPTGAAKDM4EDYRK1A
SCHEMBL7004647 0.84 MAPT (0.48) PRKCIMAPTGAAKDM4EDYRK1A
Hydrochloric Acid SCHEMBL30774268 0.82 MAPT (0.52) PRKCIMAPTGAAKDM4ECTNNB1
SCHEMBL2776414 0.77 MAPT (0.70) MAPTGAAKDM4ESMN1; SMN2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-3043458-A — — None — — JP disclosed
JP-55000330-A — — None — — JP disclosed
CN-115093389-B 6-Amide chroman-3-carboxamide derivative, preparation method and application thereof 广州医科大学 2024-10-18 — — CN disclosed
US-20230212157-A1 PYRAZOLE DERIVATIVES FOR THE TREATMENT OF CYSTIC FIBROSIS ISTITUTO GIANNINA GASLINI (IT) 2023-07-06 — — US disclosed
US-20230159456-A1 N-SUBSTITUTED INDOLES TERRAN BIOSCIENCES INC (US) 2023-05-25 — — US disclosed
US-20230159456-A1 N-SUBSTITUTED INDOLES TERRAN BIOSCIENCES INC (US) 2023-05-25 — — US disclosed
WO-2023077127-A2 N-SUBSTITUTED INDOLES TERRAN BIOSCIENCES, INC. (US) 2023-05-04 — — WO disclosed
CN-115093389-A 6-amide chroman-3-formamide derivative and preparation method and application thereof 广州医科大学 2022-09-23 — — CN disclosed
WO-2022133303-A1 COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS THE SCRIPPS RESEARCH INSTITUTE (US) 2022-06-23 — — WO disclosed
CN-109689645-B Cyanoindoline derivatives as NIK inhibitors 杨森制药有限公司 2022-06-03 — — CN disclosed
US-20020099056-A1 6-(4-arylalkylpiperazin-1-yl) benzodioxane and 6-(4-arylalkypiperazin-1-yl) chromane derivatives: dopamine receptor subtype specific ligands NEUROGEN CORPORATION 2002-07-25 — — US disclosed
US-6333329-B2 USEFUL FOR TREATMENT AND/OR PREVENTION OF NEUROPSYCHOLOGICAL DISORDERS INCLUDING SCHIZOPHRENIA, MANIA, DEMENTIA, DEPRESSION, ANXIETY, COMPULSIVE BEHAVIOR, DRUG ABUSE, PARKINSON-LIKE MOTOR DISORDERS AND MOTION DISORDERS NEUROGEN CORPORATION 2001-12-25 — — US disclosed
US-20010005753-A1 6-(4-arylalkylpiperazin-1-yl) benzodioxane and 6-(4-arylalkylpiperazin-1-yl) chromane derivatives: dopamine receptor subtype specific ligands NEUROGEN CORPORATION 2001-06-28 — — US disclosed
EP-1091949-A2 6-(4-ARYLALKYLPIPERAZIN-1-YL)BENZODIOXANE AND 6-(4-ARYLALKYLPIPERAZIN-1-YL)CHROMANE DERIVATIVES: DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS NEUROGEN CORPORATION (US) 2001-04-18 — — EP disclosed
US-6177566-B1 TREATMENT AND/OR PREVENTION OF NEUROPSYCHOLOGICAL DISORDERS NEUROGEN CORPORATION 2001-01-23 — — US disclosed
WO-2000000489-A2 6-(4-ARYLALKYLPIPERAZIN-1-YL)BENZODIOXANE AND 6-(4-ARYLALKYLPIPERAZIN-1-YL)CHROMANE DERIVATIVES: DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS NEUROGEN CORPORATION (US) 2000-01-06 — — WO disclosed
US-5532241-A Piperidines and piperazines MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1996-07-02 — — US disclosed
JP-H0343458-A OLEFINIC POLYMER COMPOSITION MITSUI PETROCHEM IND LTD 1991-02-25 — — JP disclosed
JP-S55330-A 5-FLUOROURACIL COMPOUND AND ANTITUMOR AGENT COMPRISING IT EISAI CO LTD 1980-01-05 — — JP disclosed
JP-H00343458-A — — 0001-01-01 — — JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010005753-A1 6-(4-arylalkylpiperazin-1-yl) benzodioxane and 6-(4-arylalkylpiperazin-1-yl) chromane derivatives: dopamine receptor subtype specific ligands CHRNA6, HTR2C, HTR3C PRKCI 3063/4885MAPT 1511/4885GAA 989/4885
US-20230212157-A1 PYRAZOLE DERIVATIVES FOR THE TREATMENT OF CYSTIC FIBROSIS CFTR, ABCC5, ABCC1 PRKCI 923/4885MAPT 4663/4885GAA 952/4885
US-20020099056-A1 6-(4-arylalkylpiperazin-1-yl) benzodioxane and 6-(4-arylalkypiperazin-1-yl) chromane derivatives: dopamine receptor subtype specific ligands CHRNA6, HTR3C, HTR2C PRKCI 3027/4885MAPT 1426/4885GAA 1035/4885
US-20230159456-A1 N-SUBSTITUTED INDOLES TPH2, TPH1, AANAT PRKCI 4521/4885MAPT 96/4885GAA 2344/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.